Katie Streicher

机构：AstraZeneca (France), AstraZeneca (United States) · ORCID：0000-0003-1684-2301

发表论文 152 篇 · 总被引 4560 次 · h-index 32

代表论文

Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19 (2024 · Clinical Infectious Diseases · 被引 16)
Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials (2024 · Infectious Diseases and Therapy · 被引 8)
Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial (2023 · Infectious Diseases and Therapy · 被引 8)
Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial (2024 · Infectious Diseases and Therapy · 被引 5)
Serum AZD7442 (tixagevimab–cilgavimab) concentrations and in vitro IC 50 values predict SARS‐CoV‐2 neutralising antibody titres (2024 · Clinical & Translational Immunology · 被引 5)
Effect of Tezepelumab on the Humoral Immune Response to Seasonal Quadrivalent Influenza Vaccination in Patients with Moderate to Severe Asthma: The Phase 3b VECTOR Study (2023 · Pulmonary Therapy · 被引 5)